Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and DDI of Nesolicaftor (PTI-428) in Healthy Females
NCT02846142Phase 1Completed
- Sponsor
- Proteostasis Therapeutics
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nesolicaftor in cystic fibrosis (CF) (7 arms), sponsored by Proteostasis Therapeutics. Primary endpoints: Safety and tolerability measured by adverse events and clinical assessments, Apparent terminal half-life of single oral dose and 14 more. Started Jun 2016; status: completed.
02
Drugs
nesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02846142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846142.